Engineered nasal bacteria: A new weapon against obesity?
Cristina Miralpeix, Daniela Cota
Cell Host & Microbe. 2025-04-01; 33(4): 467-469
DOI: 10.1016/j.chom.2025.03.010
Lire sur PubMed
Cell Host & Microbe. 2025-04-01; 33(4): 467-469
DOI: 10.1016/j.chom.2025.03.010
Lire sur PubMed
Miralpeix C(1), Cota D(2).
Author information:
(1)University of Bordeaux, INSERM, Neurocentre Magendie, U1215, 33000 Bordeaux,
France.
(2)University of Bordeaux, INSERM, Neurocentre Magendie, U1215, 33000 Bordeaux,
France. Electronic address: .
The nose-to-brain pathway for drug delivery holds promising therapeutic
outcomes. In a recent issue of Cell, Shen et al.1 successfully identified and
characterized a commensal bacterial strain to enable the intranasal delivery of
therapeutics, using obesity as a disease model.
Copyright © 2025 Elsevier Inc. All rights reserved.
DOI: 10.1016/j.chom.2025.03.010
PMID: 40209675 [Indexed for MEDLINE]
Conflict of interest statement: Declaration of interests The authors declare no
competing interests.